Submitted by Anonymous (not verified) on 30 September 2026 - 9:35
Human medicines European public assessment report (EPAR): Ximluci, ranibizumab, Date of authorisation: 09/11/2022, Revision: 3, Status: Authorised
Source:
Human medicines European public assessment report (EPAR): Ximluci, ranibizumab, Date of authorisation: 09/11/2022, Revision: 3, Status: Authorised